

Jay Lucidarme

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/264522/publications.pdf>

Version: 2024-02-01

41
papers

1,837
citations

361413

20
h-index

276875

41
g-index

41
all docs

41
docs citations

41
times ranked

1157
citing authors

#	ARTICLE	IF	CITATIONS
1	Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 416-425.	9.1	261
2	Increase in Endemic <i>Neisseria meningitidis</i> Capsular Group W Sequence Type 11 Complex Associated With Severe Invasive Disease in England and Wales. <i>Clinical Infectious Diseases</i> , 2015, 60, 578-585.	5.8	191
3	Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage. <i>Journal of Infection</i> , 2015, 71, 544-552.	3.3	185
4	Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England. <i>New England Journal of Medicine</i> , 2020, 382, 309-317.	27.0	154
5	The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. <i>Expert Review of Vaccines</i> , 2019, 18, 15-30.	4.4	136
6	An international invasive meningococcal disease outbreak due to a novel and rapidly expanding serogroup W strain, Scotland and Sweden, July to August 2015. <i>Eurosurveillance</i> , 2016, 21, .	7.0	98
7	Characterization of <i>Neisseria meningitidis</i> Isolates That Do Not Express the Virulence Factor and Vaccine Antigen Factor H Binding Protein. <i>Vaccine Journal</i> , 2011, 18, 1002-1014.	3.1	84
8	Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study. <i>Lancet Public Health</i> , The, 2017, 2, e473-e482.	10.0	73
9	Genomic epidemiology of age-associated meningococcal lineages in national surveillance: an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1420-1428.	9.1	63
10	Meningococcal disease surveillance in the Asia-Pacific region (2020): The global meningococcal initiative. <i>Journal of Infection</i> , 2020, 81, 698-711.	3.3	51
11	First Real-world Evidence of Meningococcal Group B Vaccine, 4CMenB, Protection Against Meningococcal Group W Disease: Prospective Enhanced National Surveillance, England. <i>Clinical Infectious Diseases</i> , 2021, 73, e1661-e1668.	5.8	45
12	Meningococcal B Vaccine Failure With a Penicillin-Resistant Strain in a Young Adult on Long-Term Eculizumab. <i>Pediatrics</i> , 2017, 140, .	2.1	38
13	Targeted DNA enrichment and whole genome sequencing of <i>Neisseria meningitidis</i> directly from clinical specimens. <i>International Journal of Medical Microbiology</i> , 2018, 308, 256-262.	3.6	36
14	Invasive meningococcal disease in patients with complement deficiencies: a case series (2008-2017). <i>BMC Infectious Diseases</i> , 2019, 19, 522.	2.9	34
15	Meningococcal disease and sexual transmission: urogenital and anorectal infections and invasive disease due to <i>Neisseria meningitidis</i> . <i>Lancet</i> , The, 2020, 395, 1865-1877.	13.7	32
16	Frequent capsule switching in "ultra-virulent" meningococci " Are we ready for a serogroup B ST-11 complex outbreak?. <i>Journal of Infection</i> , 2017, 75, 95-103.	3.3	30
17	Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe. <i>Journal of Infection</i> , 2019, 79, 528-541.	3.3	29
18	Surveillance and control of meningococcal disease in the COVID-19 era: A Global Meningococcal Initiative review. <i>Journal of Infection</i> , 2022, 84, 289-296.	3.3	26

#	ARTICLE	IF	CITATIONS
19	Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates. <i>Vaccine</i> , 2020, 38, 7542-7550.	3.8	25
20	Serogroup C <i>Neisseria meningitidis</i> disease epidemiology, seroprevalence, vaccine effectiveness and waning immunity, England, 1998/99 to 2015/16. <i>Eurosurveillance</i> , 2019, 24, .	7.0	20
21	Antibiotic resistance among invasive <i>Neisseria meningitidis</i> isolates in England, Wales and Northern Ireland (2010/11 to 2018/19). <i>PLoS ONE</i> , 2021, 16, e0260677.	2.5	19
22	Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: a national surveillance and modelling study. <i>The Lancet Child and Adolescent Health</i> , 2022, 6, 96-105.	5.6	18
23	Molecular characterization of invasive capsule null <i>Neisseria meningitidis</i> in South Africa. <i>BMC Microbiology</i> , 2017, 17, 40.	3.3	17
24	4CMenB Immunization Induces Serum Bactericidal Antibodies Against Non-Serogroup B Meningococcal Strains in Adolescents. <i>Infectious Diseases and Therapy</i> , 2021, 10, 307-316.	4.0	17
25	Genotypic Analysis of Meningococcal Factor H-Binding Protein from Non-Culture Clinical Specimens. <i>PLoS ONE</i> , 2014, 9, e89921.	2.5	16
26	Detection of the United States <i>Neisseria meningitidis</i> urethritis clade in the United Kingdom, August and December 2019 – emergence of multiple antibiotic resistance calls for vigilance. <i>Eurosurveillance</i> , 2020, 25, .	7.0	16
27	Phase Variation of <i>NadA</i> in Invasive <i>Neisseria meningitidis</i> Isolates Impacts on Coverage Estimates for 4C-MenB, a MenB Vaccine. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	14
28	Clustered intergenic region sequences as predictors of factor H Binding Protein expression patterns and for assessing <i>Neisseria meningitidis</i> strain coverage by meningococcal vaccines. <i>PLoS ONE</i> , 2018, 13, e0197186.	2.5	14
29	The global meningitis genome partnership. <i>Journal of Infection</i> , 2020, 81, 510-520.	3.3	13
30	Variable clinical presentation by the main capsular groups causing invasive meningococcal disease in England. <i>Journal of Infection</i> , 2020, 80, 182-189.	3.3	11
31	Meningococcal Serogroup A, B, C, W, X, and Y Serum Bactericidal Antibody Assays. <i>Methods in Molecular Biology</i> , 2019, 1969, 169-179.	0.9	10
32	Geographically widespread invasive meningococcal disease caused by a ciprofloxacin resistant non-groupable strain of the ST-175 clonal complex. <i>Journal of Infection</i> , 2020, 81, 575-584.	3.3	9
33	Potential of Phase Variation in Multiple Outer-Membrane Proteins During Spread of the Hyperinvasive <i>Neisseria meningitidis</i> Serogroup W ST-11 Lineage. <i>Journal of Infectious Diseases</i> , 2019, 220, 1109-1117.	4.0	8
34	Increase in penicillin-resistant invasive meningococcal serogroup W ST-11 complex isolates in England. <i>Vaccine</i> , 2021, 39, 2719-2729.	3.8	8
35	Differences between culture & non-culture confirmed invasive meningococci with a focus on factor H-binding protein distribution. <i>Journal of Infection</i> , 2016, 73, 63-70.	3.3	7
36	Correlates of protection for meningococcal surface protein vaccines: lessons from the past. <i>Expert Review of Vaccines</i> , 2022, 21, 739-751.	4.4	7

#	ARTICLE	IF	CITATIONS
37	Genomic analysis of the meningococcal ST-4821 complexâ€™Western clade, potential sexual transmission and predicted antibiotic susceptibility and vaccine coverage. PLoS ONE, 2020, 15, e0243426.	2.5	7
38	Comparative genomic analyses of Chinese serogroup W ST-11 complex Neisseria meningitidis isolates. Journal of Infection, 2020, 80, 54-60.	3.3	5
39	Invasive serogroup B meningococci in England following three years of 4CMenB vaccination â€™ first real-world data. Journal of Infection, 2021, , .	3.3	4
40	UK guidelines and testing for invasive meningococcal disease. Lancet Infectious Diseases, The, 2021, 21, 455-456.	9.1	3
41	Timing of meningococcal vaccination with 4CMenB (BexseroÂ®) in children with invasive meningococcal group B (MenB) disease in England. Vaccine, 2022, 40, 1493-1498.	3.8	3